FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely to the influence of liver failure on rifaximin pharmacokinetics. Described application of rifaximin for obtaining a medication for the treatment of a subject, suffering from, subjected to or being at a stage of remission of hepatic encephalopathy (HE), which includes the introduction of rifaximin during the period from approximately 24 weeks to 24 months in a dose of 550 mg twice per day daily.
EFFECT: medication makes it possible to reduce a risk of expressed hepatic encephalopathy in the subject.
6 cl, 19 tbl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING HEPATIC ENCEPHALOPATHY | 2010 |
|
RU2540513C2 |
| METHOD OF PREDICTING DEVELOPMENT OF CRITICAL HEPATIC FAILURE BASING ON SELENIUM LEVEL IN SERUM | 2014 |
|
RU2549963C1 |
| METHOD FOR ASSESSING THE RISK OF DEATH IN LIVER CIRRHOSIS | 2021 |
|
RU2761729C1 |
| METHOD OF ESTIMATING RISK OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT SURGERY IN PATIENTS WITH PORTAL HYPERTENSION OF CIRRHOTIC GENESIS | 2011 |
|
RU2492479C2 |
| METHOD FOR ASSESSING RISK OF UNFAVOURABLE OUTCOME FOR PATIENT WITH CIRRHOSIS ON LIVER TRANSPLANTATION WAITING LIST | 2020 |
|
RU2737582C1 |
| METHOD FOR THREE-STAGE MINIMALLY INVASIVE TREATMENT OF COMPLICATIONS OF HEPATIC CIRRHOSIS | 2023 |
|
RU2816786C1 |
| METHOD FOR PREDICTION OF FATAL OUTCOME IN PATIENTS SUFFERING FROM VIRAL AND ALCOHOLIC HEPATIC CIRRHOSIS | 2008 |
|
RU2373533C1 |
| METHOD FOR DETERMINING THE RISK OF HYPERCOAGULABILITY IN PATIENTS WITH PORTAL HYPERTENSION OF CYRRHOTIC GENESIS AFTER PORTOSYSTEMIC SHUNT PLACEMENT | 2017 |
|
RU2665118C1 |
| METHOD FOR SEVERITY DIAGNOSIS OF LIVER CIRRHOSIS OF MIXED ETIOLOGY | 2016 |
|
RU2632101C1 |
| STEROID COMPOUND FOR USE IN TREATMENT OF HEPATIC ENCEPHALOPATHY | 2015 |
|
RU2684616C2 |
